Market news

Ionis Pharmaceuticals has had a rough run so far this year, even as fresh clinical results have put its drug pipeline in the spotlight. With the share price under pressure, the real issue for investors is how well the current valuation lines up with the sales its business is generating and may be able to support over time. The stock is down about 45.0% year to date. This puts a sharp spotlight on whether today's market value still lines up with what Ionis can justify through its sales...

Novartis AG’s (NYSE:NVS) Phase 3 Lp(a)HORIZON setback carries implications beyond the Swiss drugmaker. Pelacarsen significantly lowered lipoprotein(a), or Lp(a), but failed to produce a statistically significant reduction in major cardiovascular events, according to the information provided. READ ALSO: Can a Tagrisso Combination Strengthen AstraZeneca’s Path to $80 Billion? That disconnect matters for companies developing other […]

Detailed price information for Ionis Pharmaceuticals (IONS-Q) from The Globe and Mail including charting and trades.

The results position Roche to bring a new kind of medicine to market for IgA nephropathy, a disease that’s drawn considerable attention of late from drugmakers.

IONS posts positive phase III results for two partnered drugs, with ulefnersen meeting its ALS endpoint and sefaxersen cutting proteinuria.

Ionis Pharmaceuticals Inc. (NASDAQ:IONS) and licensing partner Roche Holdings AG (OTC:RHHBY) on Wednesday shared prespecified interim outcomes from their ongoing Phase 3 IMAgINATION trial of investigational sefaxersen in adults diagnosed with primary IgA nephropathy (IgAN). "These interim phase 3 results show the clinical potential of sefaxersen to modify a key surrogate endpoint of kidney function in people with IgA nephropathy’’ said Levi Garraway, Roche’s Chief Medical Officer and Head of Glo

Ionis and Roche report positive Phase 3 IMAgINATION trial interim results for sefaxersen in treating primary IgA nephropathy.

Ionis Pharmaceuticals and Otsuka Pharmaceutical report positive Phase 3 data for ulefnersen, an investigational RNA-targeted drug for ALS.

CARLSBAD, Calif., September 22, 2026--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Otsuka Pharmaceutical Development & Commercialization, Inc., today announced positive topline results from the Phase 3 FUSION trial evaluating ulefnersen, an investigational RNA-targeted medicine, in people living with amyotrophic lateral sclerosis (ALS) caused by mutations in the fused in sarcoma (FUS) gene, also known as FUS-ALS. The study met its primary endpoint, with ulefnersen demonstrating a statistically

Shares of Ionis are down more than 40% so far this year.

Motley Fool Press Release.

On September 5, 2026, Reuters reported that pelacarsen, an experimental drug from Novartis AG (NYSE:NVS) and partner Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) meant to lower a cholesterol-carrying particle called Lp(a), failed to reduce heart attacks, strokes and related cardiovascular events in the Lp(a)HORIZON trial, which enrolled more than 8,000 patients. The drug did lower Lp(a) levels […]

Oligonucleotide Therapeutics Expand Beyond Rare Diseases as RNA Innovation, Targeted Delivery and Patient-Friendly Dosing Accelerate AdoptionDublin, Sept. 15, 2026 (GLOBE NEWSWIRE) -- "Oligonucleotide Therapeutics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026-2035" has been added to ResearchAndMarkets.com's offering. Global Oligonucleotide Therapeutics Market to Reach USD 72.1 Billion by 2035 at a 23.4% CAGR The global oligonucleotide therapeutics market was valu

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) has turned decades of RNA research into its first independently launched neurology medicine. The FDA-approved Zanvastro, chemically known as zilganersen, for adults and children with Alexander disease, has taken the lead as the first approved disease-modifying treatment for the rare neurological disorder. Ionis has set a price of $285,000 per dose […]

Novartis AG’s (NYSE:NVS) pelacarsen failed an important test. Although the experimental medicine lowered lipoprotein(a), or Lp(a), it did not produce a statistically significant reduction in cardiovascular events in the Phase 3 Lp(a)HORIZON study. Bank of America does not believe the result breaks the Novartis (NYSE:NVS) investment thesis. The firm estimates that the failed study creates […]

Ionis Pharmaceuticals is promising in multiple ways -- but it's not dirt cheap or without risks.

Ionis Pharmaceuticals (IONS) has an average rating of overweight and mean price target of $84.24, ac

Novartis and Ionis' high-profile Lp(a) flop on Friday reverberated through biotech stocks on Tuesday.

Nvidia and ASML get involved with Mistral, Ionis falls on trial results, and more...

Pelacarsen didn’t protect heart health despite lowering levels of a protein particle, “Lp(a),” in a large clinical trial — a surprise result with important implications for cardiovascular drug research.